HRP20200819T1 - Spojevi indol karboksamida korisni kao inhibitori kinaze - Google Patents

Spojevi indol karboksamida korisni kao inhibitori kinaze Download PDF

Info

Publication number
HRP20200819T1
HRP20200819T1 HRP20200819TT HRP20200819T HRP20200819T1 HR P20200819 T1 HRP20200819 T1 HR P20200819T1 HR P20200819T T HRP20200819T T HR P20200819TT HR P20200819 T HRP20200819 T HR P20200819T HR P20200819 T1 HRP20200819 T1 HR P20200819T1
Authority
HR
Croatia
Prior art keywords
indole
carboxamide
fluoro
dimethyl
piperidin
Prior art date
Application number
HRP20200819TT
Other languages
English (en)
Inventor
Saleem Ahmad
Joseph A. Tino
John E. Macor
Andrew J. Tebben
Hua Gong
Qingjie Liu
Douglas G Batt
Khehyong Ngu
Scott Hunter Watterson
Weiwei Guo
Myra Beaudoin Bertrand
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20200819T1 publication Critical patent/HRP20200819T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Claims (10)

1. Spoj Formule (I): [image] ili njegova sol ili solvat, gdje: X je CR4; A je: [image] ili [image] Q2 je -C(O)CH=CH2, -C(O)CH=CHCH2N(CH3)2, -C(O)C≡CR7, -C(O)C≡C(fenil), -C(O)C≡C(C1-3 hidroksialkil), -C(O)C≡CSi(CH3)3, ili -S(O)2CH=CH2; R1 je H, -CH3, -CF3, ili fenil supstituiran sa nula ili 1 R12; R2 je H, -CH3, ciklopropil, ili fenil supstituiran sa nula ili 1 R12, pod uvjetom da najmanje jedan od R1 i R2 je -CH3; R3 je F ili Cl; R4 je H ili F; R7, pri svakom pojavljivanju, je nezavisno H, C1-4 alkil, ili ciklopropil; i R12 je F, Cl, -CN, -CF3, ili C1-3 alkoksi.
2. Spoj prema patentnom zahtjevu 1 ili njegova sol ili solvat, gdje: R1 je CH3 i R2je CH3.
3. Spoj prema patentnom zahtjevu 1 ili njegova sol ili solvat, gdje: R3 je F.
4. Spoj prema patentnom zahtjevu 1 ili njegova sol ili solvat, gdje: R7 pri svakom pojavljivanju je H ili C1-2 alkil.
5. Spoj prema patentnom zahtjevu 1 koje ima strukturu: [image]
6. Spoj prema patentnom zahtjevu 1 ili njegova sol ili solvat, gdje navedeno spoj je odabran od: (S)-4-(3-akrilamidopiperidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (S)-4-(3-akrilamidopirolidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (S)-5-fluoro-2,3-dimetil-4-(3-(N-metilbut-2-inamido)piperidin-1-il)-1H-indol-7-karboksamid; (S)-5-fluoro-2,3-dimetil-4-(3-(pent-2-inamido) piperidin-1-il)-1H-indol-7-karboksamid; (S)-5-fluoro-2,3-dimetil-4-(3-(N-metilpent-2-inamido)piperidin-1-il)-1H-indol-7-karboksamid; (S)-5-fluoro-4-(3-(heks-2-inamido)piperidin-1-il)-2,3-dimetil-1H-indol-7-karboksamid; (S)-4-(3-(N-etilbut-2-inamido)piperidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (S)-4-(3-(but-2-inamido)pirolidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (S)-4-(3-(3-ciklopropilpropiolamido)piperidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (S)-5-fluoro-2,3-dimetil-4-(3-(vinilsulfonamido)piperidin-1-il)-1H-indol-7-karboksamid; (S)-4-(3-(N-ciklopropilbut-2-inamido)piperidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; 4-(4-(but-2-inoil)piperazin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; 4-(4-akriloilepiperazin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; 4-(1-akriloil-1,2,5,6-tetrahidropiridin-3-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; (RS)-4-(1-akriloilpiperidin-3-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; 4-(1-akriloilpiperidin-3-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid, pojedinačni enantiomeri; (RS)-4-(1-(but-2-inoil)piperidin-3-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid; i (S)-4-(3-(but-2-inamido)piperidin-1-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamid.
7. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1-6 ili njegovu farmaceutski-prihvatljivu sol ili solvat; i farmaceutski prihvatljiv nosač.
8. Spoj prema bilo kojem od patentnih zahtjeva 1-6 ili njegova farmaceutski-prihvatljiva sol ili solvat, za primjenu u terapiji.
9. Spoj prema bilo kojem od patentnih zahtjeva 1-6 ili njegova farmaceutski-prihvatljiva sol ili solvat, za primjenu u terapiji za liječenje autoimune bolesti ili kronične inflamatorne bolesti.
10. Spoj za primjenu prema patentnom zahtjevu 9 gdje navedena autoimuna bolest ili kronična inflamatorna bolest je odabrana od sistemskog eritemskog lupusa (SLE), reumatoidnog artritisa, multiple skleroze (MS), i Sjögrenovog sindroma.
HRP20200819TT 2014-10-24 2020-05-20 Spojevi indol karboksamida korisni kao inhibitori kinaze HRP20200819T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
EP15790407.9A EP3209656B1 (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhibitors
PCT/US2015/057055 WO2016065226A1 (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhobitors

Publications (1)

Publication Number Publication Date
HRP20200819T1 true HRP20200819T1 (hr) 2020-08-07

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200819TT HRP20200819T1 (hr) 2014-10-24 2020-05-20 Spojevi indol karboksamida korisni kao inhibitori kinaze
HRP20201146TT HRP20201146T1 (hr) 2014-10-24 2020-07-22 Spojevi indol karboksamida korisni kao inhibitori kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20201146TT HRP20201146T1 (hr) 2014-10-24 2020-07-22 Spojevi indol karboksamida korisni kao inhibitori kinaze

Country Status (34)

Country Link
US (8) US9688629B2 (hr)
EP (2) EP3209656B1 (hr)
JP (1) JP6517928B2 (hr)
KR (2) KR102001745B1 (hr)
CN (2) CN107108583B (hr)
AR (2) AR102426A1 (hr)
AU (2) AU2015335694B2 (hr)
CA (1) CA2965517C (hr)
CL (1) CL2017000992A1 (hr)
CO (1) CO2017004481A2 (hr)
CY (2) CY1123401T1 (hr)
DK (2) DK3461821T3 (hr)
EA (2) EA034931B1 (hr)
ES (2) ES2809974T3 (hr)
HR (2) HRP20200819T1 (hr)
HU (2) HUE050706T2 (hr)
IL (2) IL251797B (hr)
LT (2) LT3209656T (hr)
MA (2) MA47043B1 (hr)
ME (2) ME03807B (hr)
MX (2) MX2017005259A (hr)
MY (2) MY195561A (hr)
PE (2) PE20170695A1 (hr)
PH (2) PH12017500725B1 (hr)
PL (2) PL3209656T3 (hr)
PT (2) PT3461821T (hr)
RS (2) RS60629B1 (hr)
SG (3) SG10201903578VA (hr)
SI (2) SI3461821T1 (hr)
TN (2) TN2017000119A1 (hr)
TW (2) TWI743401B (hr)
UY (1) UY36371A (hr)
WO (1) WO2016065226A1 (hr)
ZA (1) ZA201804893B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151990A1 (es) 2013-03-15 2016-01-13 Incyte Corp Heterociclos triciclicos como inhibidores de la proteina bet
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
CR20160542A (es) 2014-04-23 2017-04-25 Incyte Corp 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
EA032361B1 (ru) 2014-10-24 2019-05-31 Бристол-Майерс Сквибб Компани Трициклические соединения
WO2016063933A1 (ja) 2014-10-24 2016-04-28 武田薬品工業株式会社 複素環化合物
BR112017007563A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co compostos atropisômeros tricíclicos
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
CA3220957A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
DK3507282T3 (da) * 2016-09-02 2021-02-01 Bristol Myers Squibb Co Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP7105359B2 (ja) * 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
KR20220110251A (ko) * 2019-12-04 2022-08-05 앱티닉스 인크. 신경변성 질환과 연관된 인지 장애를 치료하는 방법
WO2021247748A1 (en) * 2020-06-02 2021-12-09 Gb005, Inc. Kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
WO2022089620A1 (zh) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 吲哚基甲酰胺类化合物的新晶型及其制备方法
WO2022155111A1 (en) * 2021-01-12 2022-07-21 Gb005, Inc. Indole derivatives as kinase inhibitors
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
KR20240054325A (ko) 2021-08-30 2024-04-25 브리스톨-마이어스 스큅 컴퍼니 브루톤 티로신 키나제의 pet-영상화에 유용한 화합물
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006064355A2 (en) 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
KR101357524B1 (ko) 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
RU2007140734A (ru) 2005-04-06 2009-05-20 Астразенека Аб (Se) Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak
CN101247804B (zh) * 2005-06-30 2012-09-26 史密丝克莱恩比彻姆公司 化学化合物
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
AU2007297221B2 (en) 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
JP2010522241A (ja) * 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
CN101687036A (zh) 2007-04-27 2010-03-31 阿斯利康(瑞典)有限公司 治疗恶性血液病的chk1抑制剂与b细胞耗尽抗体
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US8431569B2 (en) 2007-12-13 2013-04-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
WO2010080481A1 (en) * 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5902704B2 (ja) 2010-11-15 2016-04-13 ヴィーブ ヘルスケア ユーケー リミテッド Ｈｉｖ複製の阻害剤
EP2702042A1 (en) 2011-04-28 2014-03-05 Bristol-Myers Squibb Company Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
KR101585753B1 (ko) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
EP2729466B1 (en) 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9447039B2 (en) * 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
MX2015016771A (es) 2013-06-25 2016-03-31 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.

Also Published As

Publication number Publication date
MA47043B1 (fr) 2021-09-30
ES2809974T3 (es) 2021-03-08
ME03740B (me) 2021-01-20
AU2015335694B2 (en) 2020-04-02
CN107108583A (zh) 2017-08-29
TN2018000218A1 (en) 2019-10-04
US20210107891A1 (en) 2021-04-15
CN110511209B (zh) 2022-07-05
PE20170695A1 (es) 2017-05-26
JP2017531679A (ja) 2017-10-26
US9802915B2 (en) 2017-10-31
KR20180132167A (ko) 2018-12-11
AU2015335694A1 (en) 2017-06-08
SG10201903579SA (en) 2019-05-30
EP3461821A1 (en) 2019-04-03
US20230192645A1 (en) 2023-06-22
PH12020500265A1 (en) 2021-02-22
KR102001745B1 (ko) 2019-07-18
ZA201804893B (en) 2020-07-29
CY1123401T1 (el) 2021-12-31
US20160115126A1 (en) 2016-04-28
KR20170061175A (ko) 2017-06-02
US20190119245A1 (en) 2019-04-25
MX2017005259A (es) 2017-07-26
EA201790740A1 (ru) 2017-08-31
US20190248760A1 (en) 2019-08-15
US20170260160A1 (en) 2017-09-14
KR102030305B1 (ko) 2019-10-08
IL262206B (en) 2020-07-30
HUE050592T2 (hu) 2020-12-28
RS60629B1 (sr) 2020-09-30
US9920031B2 (en) 2018-03-20
UY36371A (es) 2016-04-29
DK3461821T3 (da) 2020-08-17
EA032277B1 (ru) 2019-05-31
US11623921B2 (en) 2023-04-11
EP3461821B1 (en) 2020-05-13
SG11201703188QA (en) 2017-05-30
PT3209656T (pt) 2020-06-08
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
JP6517928B2 (ja) 2019-05-22
MY195561A (en) 2023-02-02
AR120317A2 (es) 2022-02-09
TW201900612A (zh) 2019-01-01
TWI744218B (zh) 2021-11-01
EP3209656B1 (en) 2020-04-01
MA40301A1 (fr) 2019-03-29
RS60312B1 (sr) 2020-07-31
US10329274B2 (en) 2019-06-25
SI3209656T1 (sl) 2020-07-31
SI3461821T1 (sl) 2020-09-30
IL251797B (en) 2020-07-30
US20200165222A1 (en) 2020-05-28
EA201892207A1 (ru) 2019-02-28
CN107108583B (zh) 2020-11-13
TWI743401B (zh) 2021-10-21
PE20190710A1 (es) 2019-05-17
ME03807B (me) 2021-04-20
LT3209656T (lt) 2020-07-27
IL251797A0 (en) 2017-06-29
MY188048A (en) 2021-11-12
DK3209656T3 (da) 2020-07-13
MA40301B1 (fr) 2019-12-31
CA2965517C (en) 2023-05-02
EP3209656A1 (en) 2017-08-30
HUE050706T2 (hu) 2020-12-28
CA2965517A1 (en) 2016-04-28
CO2017004481A2 (es) 2017-08-10
ES2795366T3 (es) 2020-11-23
US10604504B2 (en) 2020-03-31
PT3461821T (pt) 2020-08-05
AU2019283921B2 (en) 2021-01-07
TN2017000119A1 (en) 2018-07-04
AR102426A1 (es) 2017-03-01
IL262206A (en) 2018-11-29
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
CN110511209A (zh) 2019-11-29
PL3461821T3 (pl) 2020-10-19
CY1123395T1 (el) 2021-12-31
US9688629B2 (en) 2017-06-27
SG10201903578VA (en) 2019-05-30
MA47043A1 (fr) 2021-03-31
AU2019283921A1 (en) 2020-01-16
CL2017000992A1 (es) 2017-11-17
MX2020008024A (es) 2022-06-10
WO2016065226A8 (en) 2017-04-27
WO2016065226A1 (en) 2016-04-28
LT3461821T (lt) 2020-08-10
EA034931B1 (ru) 2020-04-08
BR112017007956A2 (pt) 2017-12-19
NZ731946A (en) 2021-02-26
TW201630880A (zh) 2016-09-01
HRP20201146T1 (hr) 2020-10-30

Similar Documents

Publication Publication Date Title
HRP20200819T1 (hr) Spojevi indol karboksamida korisni kao inhibitori kinaze
HRP20211583T1 (hr) Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
JP2016536364A5 (hr)
JP2017511357A5 (hr)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
RU2014148316A (ru) Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
JP2015504067A5 (hr)
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
JP2016507581A5 (hr)
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
HRP20190900T1 (hr) Trifluorometil alkoholi kao modulatori ror-gama-t
MX2009008509A (es) Compuesto de anillo puenteado-aza.
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
HRP20171647T1 (hr) Piridinil- i pirazinilmetiloksiarilni derivati, korisni kao inhibitori slezenske tirozinske kinaze (syk)
JP2020521766A5 (hr)
JP2012527487A5 (hr)